Singapore, Dec. 22 -- Researchers in Australia have developed a new antimalarial drug candidate designed to address the growing challenge of drug resistance and potentially reduce malaria transmission.

The first-in-class clinical candidate, MK-7602, has been developed through a longstanding collaboration betweenWalter and Eliza Hall Institute of Medical Research (WEHI) and global biopharmaceutical company MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA).

Published by HT Digital Content Services with permission from BioSpectrum Asia....